Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting

doi:10.1371/journal.pone.0237582

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24420

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24420

Title:	Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting
Authors:	Yen, HH;Su, PY;Zeng, YH;Liu, IL;Huang, SP;Hsu, YC;Chen, YY;Yang, CW;Wu, SS;Chou, KC
Date:	2020
Issue Date:	2022-08-09T08:02:00Z (UTC)
Publisher:	PUBLIC LIBRARY SCIENCE
ISSN:	1932-6203
Abstract:	Introduction Chronic hepatitis C virus (HCV) infection is increasingly observed in patients with renal disease. With the introduction of glecaprevir/pibrentasvir (GLE/PIB) as a pan-genotype therapy for HCV, treatment efficacy is expected to rise. Materials and methods This retrospective study evaluated the efficacy and safety of GLE/PIB treatment in adults with HCV infection and end-stage renal disease (ESRD). The primary end point was sustained virological response (SVR) observed 12 weeks after completed treatment. Results We enrolled 235 patients, including 44 patients with ESRD. Median age was 60 years, and 48% were males. Twenty-two percent had cirrhosis. HCV genotypes 1 (43%) and 2 (41%) were the most common. The overall SVR rate was 96.6%. Patients with ESRD were older than those without (67.6 yearsvs58.3 years, p < 0.001) and trended toward having a higher prevalence of cirrhosis (32%vs19%, p = 0.071). A significant proportion of patients with ESRD complained of skin itching during treatment (61%vs26%, p < 0.001), and the SVR rate were similar between these two groups (95.45%vs96.86%, p = 0.644). Conclusions Despite a higher rate of pruritus among patients with ESRD, GLE/PIB-based therapy achieved similarly high SVR rates among patients with and without ESRD.
URI:	http://dx.doi.org/10.1371/journal.pone.0237582 https://www.webofscience.com/wos/woscc/full-record/WOS:000562668300058 https://ir.csmu.edu.tw:8080/handle/310902500/24420
Relation:	PLOS ONE ,2020 ,v15 ,issue 8
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	235	View/Open

Loading...